Second All-Oral Hep C Treatment Available: Less Expensive
November 13, 2014
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
By Anna Edney
Johnson & Johnson (JNJ) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.
The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.
Continue reading this entire article:
Harvoni Is Here: The Once-a-Day, Single Hep C Pill
A Win for Liver Transplant Patients with Hepatitis C